All in the family

GT389-255, a dual lipase inhibitor and fat binder, has snaked its way through GelTex Pharmaceuticals Inc. and Genzyme Corp. and now has stopped over at Peptimmune Inc. However, the compound is not yet at rest because the obesity market probably is best handled by big pharma.

Last week, GENZ granted Peptimmune an exclusive worldwide license to develop and market GT389-255 to treat obesity. GENZ is eligible for royalties, plus shared milestones and additional payments if the program is sublicensed. ...